Symbols / EVGN $0.81 +3.61% Evogene Ltd.
EVGN Chart
About
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Israel, Brazil, and internationally. The company focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through its computational predictive biology (CPB) platform. It operates through three segments: Agriculture, Human Health, and other Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, gastrointestinal inflammatory related disorders, and antimicrobial resistance organisms. The Industrial Applications segment focuses on the development and commercialization of improved castor bean seeds for industrial uses. The company also provides medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop Novel Therapies for for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD). Evogene Ltd. was incorporated in 1999 and is headquartered in Rehovot, Israel.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 8.01M |
| Enterprise Value | 9.05M | Income | -14.16M | Sales | 3.85M |
| Book/sh | -0.01 | Cash/sh | 1.31 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -1.01 | PEG | — |
| P/S | 2.08 | P/B | -90.00 | P/C | — |
| EV/EBITDA | -0.68 | EV/Sales | 2.35 | Quick Ratio | 3.96 |
| Current Ratio | 4.54 | Debt/Eq | 18.36 | LT Debt/Eq | — |
| EPS (ttm) | -1.70 | EPS next Y | -0.80 | EPS Growth | — |
| Revenue Growth | -80.50% | Earnings | 2026-05-21 | ROA | -28.77% |
| ROE | -100.69% | ROIC | — | Gross Margin | -6.25% |
| Oper. Margin | -15.82% | Profit Margin | -220.22% | Shs Outstand | 9.89M |
| Shs Float | 9.81M | Short Float | 2.78% | Short Ratio | 1.84 |
| Short Interest | — | 52W High | 2.42 | 52W Low | 0.72 |
| Beta | 0.95 | Avg Volume | 488.60K | Volume | 31.57K |
| Target Price | $1.75 | Recom | None | Prev Close | $0.78 |
| Price | $0.81 | Change | 3.61% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-05-22 | main | Lake Street | Buy → Buy | $4 |
| 2024-08-23 | main | Lake Street | Buy → Buy | $12 |
| 2023-10-02 | init | Alliance Global Partners | — → Buy | $2 |
| 2023-08-18 | main | Lake Street | Buy → Buy | $3 |
| 2023-07-21 | main | Roth MKM | Buy → Buy | $6 |
| 2023-05-02 | init | Lake Street | — → Buy | $2 |
| 2022-09-12 | main | Aegis Capital | — → Buy | $8 |
| 2022-09-02 | main | Roth MKM | Buy → Buy | $3 |
| 2021-10-08 | init | Roth Capital | — → Buy | $7 |
| 2021-07-29 | init | Aegis Capital | — → Buy | $10 |
| 2020-12-01 | init | Cantor Fitzgerald | — → Overweight | $9 |
- [EFFECT] Evogene Ltd. SEC Filing - Stock Titan Mon, 06 Apr 2026 04
- Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification - PR Newswire hu, 02 Apr 2026 20
- Evogene stock soars after licensing deal for cancer therapeutic - Investing.com hu, 02 Apr 2026 07
- Nasdaq gives Evogene until Sept. 28 to fix its sub-$1 stock price - Stock Titan hu, 02 Apr 2026 20
- Why Did EVGN Shares Drop More Than 14% Today? - Stocktwits ue, 10 Feb 2026 20
- Nasdaq warns Evogene (NASDAQ: EVGN) over $1.00 minimum bid rule - Stock Titan hu, 02 Apr 2026 20
- Brazil field trials show castor oil can scale as a biofuel feedstock - Stock Titan ue, 31 Mar 2026 12
- EVGN SEC Filings - Evogene 10-K, 10-Q, 8-K Forms - Stock Titan ue, 31 Mar 2026 02
- AI drug designer Evogene slashes costs as it sells side businesses - Stock Titan hu, 05 Mar 2026 08
- Evogene (EVGN) chief development officer reports 40,000-share stock option grant - Stock Titan Wed, 18 Mar 2026 07
- AI-designed drugs and herbicides: inside Evogene’s new focus - Stock Titan Wed, 25 Feb 2026 08
- How Evogene uses AI to design drugs, on show at BIO-Europe 2026 - Stock Titan Mon, 09 Mar 2026 07
- [Form 3] Evogene Ltd. Initial Statement of Beneficial Ownership - Stock Titan Wed, 18 Mar 2026 07
- If You Invested $1,000 in Evogene (EVGN) - Stock Titan Sun, 22 Mar 2026 16
- Evogene (EVGN) director Nir details multiple stock option grants in Form 3 - Stock Titan Wed, 18 Mar 2026 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
3.85
-30.91%
|
5.58
+87.02%
|
2.98
+78.03%
|
1.68
|
| Operating Revenue |
|
3.85
-30.91%
|
5.58
+87.02%
|
2.98
+78.03%
|
1.68
|
| Cost Of Revenue |
|
4.09
+72.02%
|
2.38
+59.73%
|
1.49
+63.92%
|
0.91
|
| Reconciled Cost Of Revenue |
|
4.09
+72.02%
|
2.38
+59.73%
|
1.49
+63.92%
|
0.91
|
| Gross Profit |
|
-0.24
-107.54%
|
3.20
+114.28%
|
1.49
+94.78%
|
0.77
|
| Operating Expense |
|
13.79
-37.31%
|
22.00
-7.26%
|
23.72
-14.38%
|
27.71
|
| Research And Development |
|
7.99
-36.10%
|
12.51
-22.75%
|
16.20
-22.10%
|
20.79
|
| Selling General And Administration |
|
5.76
-35.81%
|
8.98
+19.25%
|
7.53
-27.73%
|
10.41
|
| Selling And Marketing Expense |
|
0.18
-17.41%
|
0.22
+38.27%
|
0.16
+22.73%
|
0.13
|
| General And Administrative Expense |
|
5.58
-36.28%
|
8.75
+18.83%
|
7.37
-28.38%
|
10.28
|
| Salaries And Wages |
|
0.84
-43.16%
|
1.49
-2.37%
|
1.52
-74.64%
|
6.00
|
| Other Gand A |
|
4.73
-34.87%
|
7.27
+24.35%
|
5.84
+36.35%
|
4.29
|
| Other Operating Expenses |
|
0.04
-92.80%
|
0.51
|
—
|
-3.50
|
| Total Expenses |
|
17.89
-26.64%
|
24.38
-3.30%
|
25.21
-11.89%
|
28.62
|
| Operating Income |
|
-14.03
+25.37%
|
-18.80
+15.42%
|
-22.23
+17.48%
|
-26.94
|
| Total Operating Income As Reported |
|
-14.03
+25.37%
|
-18.80
+15.42%
|
-22.23
+17.48%
|
-26.94
|
| EBITDA |
|
-12.20
+8.73%
|
-13.36
+34.91%
|
-20.53
+23.98%
|
-27.01
|
| Normalized EBITDA |
|
-14.06
+17.93%
|
-17.13
+14.79%
|
-20.10
+17.73%
|
-24.43
|
| Reconciled Depreciation |
|
1.14
-17.16%
|
1.38
+6.23%
|
1.30
-49.61%
|
2.58
|
| EBIT |
|
-13.34
+9.52%
|
-14.74
+32.46%
|
-21.83
+26.22%
|
-29.59
|
| Total Unusual Items |
|
1.86
-50.58%
|
3.76
+975.35%
|
-0.43
+83.31%
|
-2.58
|
| Total Unusual Items Excluding Goodwill |
|
1.86
-50.58%
|
3.76
+975.35%
|
-0.43
+83.31%
|
-2.58
|
| Net Income |
|
-8.48
+48.53%
|
-16.48
+30.96%
|
-23.88
+10.36%
|
-26.64
|
| Pretax Income |
|
-13.50
+8.85%
|
-14.81
+32.53%
|
-21.95
+26.24%
|
-29.75
|
| Net Non Operating Interest Income Expense |
|
-1.28
-574.17%
|
0.27
-62.10%
|
0.71
+401.69%
|
-0.24
|
| Interest Expense Non Operating |
|
0.16
+149.21%
|
0.06
-44.74%
|
0.11
-30.91%
|
0.17
|
| Net Interest Income |
|
-1.28
-574.17%
|
0.27
-62.10%
|
0.71
+401.69%
|
-0.24
|
| Interest Expense |
|
0.16
+149.21%
|
0.06
-44.74%
|
0.11
-30.91%
|
0.17
|
| Interest Income Non Operating |
|
0.36
-56.32%
|
0.81
-16.67%
|
0.98
+437.36%
|
0.18
|
| Interest Income |
|
0.36
-56.32%
|
0.81
-16.67%
|
0.98
+437.36%
|
0.18
|
| Other Income Expense |
|
1.82
-51.11%
|
3.73
+966.28%
|
-0.43
+83.31%
|
-2.58
|
| Gain On Sale Of Security |
|
1.86
-50.58%
|
3.76
+975.35%
|
-0.43
+83.31%
|
-2.58
|
| Tax Provision |
|
0.00
-88.89%
|
0.01
-52.63%
|
0.02
-78.89%
|
0.09
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.43
-50.58%
|
0.87
+975.35%
|
-0.10
+83.31%
|
-0.59
|
| Net Income Including Noncontrolling Interests |
|
-7.83
+56.65%
|
-18.05
+30.44%
|
-25.95
+13.03%
|
-29.84
|
| Net Income From Continuing Operation Net Minority Interest |
|
-14.16
-6.86%
|
-13.25
+33.39%
|
-19.89
+25.33%
|
-26.64
|
| Net Income From Continuing And Discontinued Operation |
|
-8.48
+48.53%
|
-16.48
+30.96%
|
-23.88
+10.36%
|
-26.64
|
| Net Income Continuous Operations |
|
-13.50
+8.90%
|
-14.82
+32.54%
|
-21.96
+26.40%
|
-29.84
|
| Net Income Discontinuous Operations |
|
5.67
+275.22%
|
-3.24
+18.85%
|
-3.99
|
—
|
| Minority Interests |
|
-0.66
-141.94%
|
1.57
-24.39%
|
2.08
-35.28%
|
3.21
|
| Normalized Income |
|
-15.59
+3.45%
|
-16.15
+17.45%
|
-19.56
+20.67%
|
-24.65
|
| Net Income Common Stockholders |
|
-8.48
+48.53%
|
-16.48
+30.96%
|
-23.88
+10.36%
|
-26.64
|
| Diluted EPS |
|
-1.08
+62.63%
|
-2.89
+44.42%
|
-5.20
+20.00%
|
-6.50
|
| Basic EPS |
|
-1.08
+62.63%
|
-2.89
+44.42%
|
-5.20
+20.00%
|
-6.50
|
| Basic Average Shares |
|
7.87
+38.21%
|
5.70
+24.71%
|
4.57
+10.86%
|
4.12
|
| Diluted Average Shares |
|
7.87
+38.21%
|
5.70
+24.71%
|
4.57
+10.86%
|
4.12
|
| Diluted NI Availto Com Stockholders |
|
-8.48
+48.53%
|
-16.48
+30.96%
|
-23.88
+10.36%
|
-26.64
|
| Earnings From Equity Interest |
|
-0.04
+0.00%
|
-0.04
|
0.00
|
0.00
|
| Total Other Finance Cost |
|
1.48
+208.52%
|
0.48
+222.82%
|
0.15
-41.34%
|
0.25
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
20.05
-49.71%
|
39.86
-21.99%
|
51.10
-8.95%
|
56.13
|
| Current Assets |
|
15.63
-27.60%
|
21.59
-37.37%
|
34.47
-8.69%
|
37.75
|
| Cash Cash Equivalents And Short Term Investments |
|
12.96
-15.33%
|
15.30
-50.74%
|
31.06
-12.14%
|
35.35
|
| Cash And Cash Equivalents |
|
12.96
-15.33%
|
15.30
-26.34%
|
20.77
-28.32%
|
28.98
|
| Cash Financial |
|
12.96
-15.33%
|
15.30
-26.34%
|
20.77
-28.32%
|
28.98
|
| Other Short Term Investments |
|
—
|
0.01
-99.90%
|
10.29
+61.43%
|
6.38
|
| Receivables |
|
1.38
-7.33%
|
1.49
+84.95%
|
0.80
+0.12%
|
0.80
|
| Accounts Receivable |
|
0.32
-70.94%
|
1.09
+205.60%
|
0.36
+2.59%
|
0.35
|
| Other Receivables |
|
1.06
+167.93%
|
0.40
-11.41%
|
0.45
-1.76%
|
0.46
|
| Accrued Interest Receivable |
|
—
|
—
|
1.62
|
0.00
|
| Inventory |
|
0.21
-88.46%
|
1.82
+2293.42%
|
0.08
-86.57%
|
0.57
|
| Prepaid Assets |
|
0.50
-69.78%
|
1.67
-33.97%
|
2.53
+153.87%
|
0.99
|
| Current Deferred Assets |
|
0.55
-57.75%
|
1.30
|
0.00
|
—
|
| Restricted Cash |
|
0.03
+220.00%
|
0.01
|
0.00
-100.00%
|
0.03
|
| Total Non Current Assets |
|
4.42
-75.84%
|
18.27
+9.88%
|
16.63
-9.49%
|
18.38
|
| Net PPE |
|
2.64
-37.99%
|
4.25
+23.76%
|
3.44
-15.54%
|
4.07
|
| Gross PPE |
|
23.20
-7.94%
|
25.20
-3.06%
|
26.00
+3.65%
|
25.08
|
| Accumulated Depreciation |
|
-20.57
+1.85%
|
-20.95
+7.14%
|
-22.56
-7.36%
|
-21.02
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
3.34
-6.71%
|
3.58
+4.65%
|
3.42
+12.47%
|
3.04
|
| Other Properties |
|
3.83
-29.40%
|
5.43
+8.77%
|
4.99
+7.28%
|
4.66
|
| Leases |
|
16.03
-1.02%
|
16.19
-7.92%
|
17.59
+1.13%
|
17.39
|
| Goodwill And Other Intangible Assets |
|
0.00
-100.00%
|
12.20
-7.40%
|
13.17
-6.87%
|
14.14
|
| Other Intangible Assets |
|
—
|
12.20
-7.40%
|
13.17
-6.87%
|
14.14
|
| Investments And Advances |
|
0.04
-47.56%
|
0.08
|
0.00
|
—
|
| Long Term Equity Investment |
|
0.04
-47.56%
|
0.08
|
0.00
|
—
|
| Non Current Accounts Receivable |
|
—
|
—
|
—
|
0.07
|
| Non Current Deferred Assets |
|
1.17
-32.85%
|
1.74
|
0.00
-100.00%
|
0.09
|
| Non Current Deferred Taxes Assets |
|
—
|
1.74
|
0.00
-100.00%
|
0.09
|
| Non Current Prepaid Assets |
|
0.57
+4658.33%
|
0.01
-57.14%
|
0.03
-62.16%
|
0.07
|
| Total Liabilities Net Minority Interest |
|
8.07
-67.75%
|
25.03
+11.64%
|
22.42
+5.06%
|
21.34
|
| Current Liabilities |
|
3.44
-81.58%
|
18.70
+169.23%
|
6.94
+23.45%
|
5.62
|
| Payables And Accrued Expenses |
|
1.95
-53.33%
|
4.18
-21.81%
|
5.34
+15.11%
|
4.64
|
| Payables |
|
1.09
-52.84%
|
2.31
-17.72%
|
2.80
+5.69%
|
2.65
|
| Accounts Payable |
|
0.64
-47.96%
|
1.23
-31.20%
|
1.78
+72.30%
|
1.04
|
| Other Payable |
|
0.45
-58.39%
|
1.08
+5.89%
|
1.02
-36.98%
|
1.62
|
| Current Accrued Expenses |
|
0.86
-53.93%
|
1.87
-26.33%
|
2.54
+27.68%
|
1.99
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
—
|
—
|
2.54
+27.68%
|
1.99
|
| Current Debt And Capital Lease Obligation |
|
0.72
-93.47%
|
10.96
+1184.88%
|
0.85
-3.51%
|
0.88
|
| Current Debt |
|
—
|
10.37
|
—
|
—
|
| Other Current Borrowings |
|
—
|
10.37
|
—
|
—
|
| Current Capital Lease Obligation |
|
0.72
+21.56%
|
0.59
-30.95%
|
0.85
-3.51%
|
0.88
|
| Current Deferred Liabilities |
|
0.07
-89.31%
|
0.68
-8.93%
|
0.75
+642.57%
|
0.10
|
| Current Deferred Revenue |
|
0.07
-89.31%
|
0.68
-8.93%
|
0.75
+642.57%
|
0.10
|
| Other Current Liabilities |
|
0.71
-75.45%
|
2.88
|
—
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
4.63
-26.92%
|
6.33
-59.08%
|
15.47
-1.52%
|
15.71
|
| Long Term Debt And Capital Lease Obligation |
|
1.48
-22.57%
|
1.91
-82.03%
|
10.65
-3.56%
|
11.05
|
| Long Term Debt |
|
—
|
—
|
10.37
+2.51%
|
10.11
|
| Long Term Capital Lease Obligation |
|
1.48
-22.57%
|
1.91
+571.58%
|
0.28
-69.42%
|
0.93
|
| Non Current Deferred Liabilities |
|
3.15
-28.80%
|
4.42
-8.34%
|
4.82
+3.30%
|
4.67
|
| Non Current Deferred Revenue |
|
3.07
-28.98%
|
4.33
-2.24%
|
4.43
-5.12%
|
4.67
|
| Stockholders Equity |
|
-0.08
+94.35%
|
-1.45
-112.04%
|
12.05
-56.85%
|
27.93
|
| Common Stock Equity |
|
-0.08
+94.35%
|
-1.45
-112.04%
|
12.05
-56.85%
|
27.93
|
| Capital Stock |
|
0.49
+34.44%
|
0.36
+26.92%
|
0.29
+21.70%
|
0.23
|
| Common Stock |
|
0.49
+34.44%
|
0.36
+26.92%
|
0.29
+21.70%
|
0.23
|
| Share Issued |
|
8.72
+33.83%
|
6.51
+28.79%
|
5.06
+22.60%
|
4.13
|
| Ordinary Shares Number |
|
8.72
+33.83%
|
6.51
+28.79%
|
5.06
+22.60%
|
4.13
|
| Additional Paid In Capital |
|
281.99
+3.57%
|
272.26
+1.08%
|
269.35
+3.04%
|
261.40
|
| Retained Earnings |
|
-282.56
-3.10%
|
-274.07
-6.40%
|
-257.59
-10.22%
|
-233.71
|
| Minority Interest |
|
12.06
-25.98%
|
16.29
-2.06%
|
16.63
+142.45%
|
6.86
|
| Total Equity Gross Minority Interest |
|
11.97
-19.30%
|
14.84
-48.27%
|
28.68
-17.55%
|
34.79
|
| Total Capitalization |
|
-0.08
+94.35%
|
-1.45
-106.47%
|
22.42
-41.07%
|
38.04
|
| Working Capital |
|
12.19
+321.11%
|
2.89
-89.49%
|
27.52
-14.32%
|
32.13
|
| Invested Capital |
|
-0.08
-100.92%
|
8.92
-60.22%
|
22.42
-41.07%
|
38.04
|
| Total Debt |
|
2.20
-82.93%
|
12.87
+11.89%
|
11.51
-3.55%
|
11.93
|
| Capital Lease Obligations |
|
2.20
-12.19%
|
2.50
+119.95%
|
1.14
-37.33%
|
1.82
|
| Net Tangible Assets |
|
-0.08
+99.40%
|
-13.65
-1122.76%
|
-1.12
-108.09%
|
13.79
|
| Tangible Book Value |
|
-0.08
+99.40%
|
-13.65
-1122.76%
|
-1.12
-108.09%
|
13.79
|
| Investmentsin Associatesat Cost |
|
—
|
0.08
|
0.00
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-13.50
+31.46%
|
-19.70
+8.70%
|
-21.58
+8.87%
|
-23.68
|
| Cash Flow From Continuing Operating Activities |
|
-11.39
+35.00%
|
-17.52
+10.38%
|
-19.55
+17.44%
|
-23.68
|
| Cash From Discontinued Operating Activities |
|
-2.12
+3.03%
|
-2.18
-7.49%
|
-2.03
|
—
|
| Net Income From Continuing Operations |
|
-13.50
+8.90%
|
-14.82
+32.54%
|
-21.96
+26.40%
|
-29.84
|
| Depreciation Amortization Depletion |
|
1.14
-17.16%
|
1.38
+6.23%
|
1.30
-49.61%
|
2.58
|
| Depreciation |
|
1.14
-17.16%
|
1.38
+6.23%
|
1.30
-14.08%
|
1.51
|
| Amortization Cash Flow |
|
—
|
0.97
+0.31%
|
0.97
-9.00%
|
1.07
|
| Depreciation And Amortization |
|
1.14
-17.16%
|
1.38
+6.23%
|
1.30
-49.61%
|
2.58
|
| Amortization Of Intangibles |
|
—
|
0.97
+0.31%
|
0.97
-9.00%
|
1.07
|
| Other Non Cash Items |
|
-0.36
+53.26%
|
-0.77
-88.70%
|
-0.41
-113.13%
|
3.10
|
| Stock Based Compensation |
|
0.65
-47.39%
|
1.24
+12.18%
|
1.11
-6.58%
|
1.19
|
| Asset Impairment Charge |
|
2.43
|
0.00
|
0.00
|
—
|
| Deferred Tax |
|
-0.01
-166.67%
|
0.01
+127.27%
|
-0.03
-136.67%
|
0.09
|
| Deferred Income Tax |
|
-0.01
-166.67%
|
0.01
+127.27%
|
-0.03
-136.67%
|
0.09
|
| Operating Gains Losses |
|
-0.63
+77.65%
|
-2.81
-10707.69%
|
-0.03
|
—
|
| Gain Loss On Investment Securities |
|
-0.46
+86.43%
|
-3.37
|
—
|
—
|
| Gain Loss On Sale Of PPE |
|
-0.21
-139.81%
|
0.53
+2119.23%
|
-0.03
|
0.00
|
| Change In Working Capital |
|
-1.25
+52.05%
|
-2.61
-839.93%
|
-0.28
+63.94%
|
-0.77
|
| Change In Receivables |
|
1.71
+856.42%
|
0.18
+114.29%
|
-1.25
-219.79%
|
1.05
|
| Changes In Account Receivables |
|
0.67
+206.06%
|
-0.63
-8857.14%
|
-0.01
+89.55%
|
-0.07
|
| Change In Inventory |
|
-1.02
+20.20%
|
-1.28
-361.15%
|
0.49
+203.16%
|
-0.47
|
| Change In Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Change In Payables And Accrued Expense |
|
-1.58
-65.79%
|
-0.96
-223.51%
|
0.77
+170.62%
|
-1.10
|
| Change In Accrued Expense |
|
-0.76
-37.96%
|
-0.55
-203.01%
|
0.53
+178.81%
|
-0.68
|
| Change In Payable |
|
-0.83
-103.19%
|
-0.41
-268.60%
|
0.24
+157.48%
|
-0.42
|
| Change In Account Payable |
|
-0.26
+58.89%
|
-0.63
-183.22%
|
0.76
+261.41%
|
-0.47
|
| Change In Other Working Capital |
|
-0.36
+35.42%
|
-0.56
-94.10%
|
-0.29
-16.60%
|
-0.25
|
| Investing Cash Flow |
|
17.74
+84.35%
|
9.62
+312.03%
|
-4.54
-134.19%
|
13.27
|
| Cash Flow From Continuing Investing Activities |
|
-0.01
-100.06%
|
9.57
+321.11%
|
-4.33
-132.62%
|
13.27
|
| Cash From Discontinued Investing Activities |
|
17.74
+36866.67%
|
0.05
+123.08%
|
-0.21
|
—
|
| Net PPE Purchase And Sale |
|
-0.06
+90.75%
|
-0.62
-11.80%
|
-0.55
+52.95%
|
-1.17
|
| Purchase Of PPE |
|
-0.14
+78.43%
|
-0.63
-8.49%
|
-0.58
+50.73%
|
-1.17
|
| Sale Of PPE |
|
0.08
+680.00%
|
0.01
-61.54%
|
0.03
|
0.00
|
| Capital Expenditure |
|
-0.14
+78.43%
|
-0.63
-8.49%
|
-0.58
+50.73%
|
-1.17
|
| Net Investment Purchase And Sale |
|
-0.00
-100.01%
|
10.19
+369.65%
|
-3.78
-126.16%
|
14.45
|
| Purchase Of Investment |
|
-0.00
+99.99%
|
-17.15
+12.96%
|
-19.70
-2062.79%
|
-0.91
|
| Sale Of Investment |
|
0.00
-100.00%
|
27.34
+71.69%
|
15.92
+3.70%
|
15.36
|
| Net Other Investing Changes |
|
0.05
|
—
|
—
|
—
|
| Financing Cash Flow |
|
-6.60
-241.80%
|
4.66
-74.35%
|
18.15
+94.28%
|
9.34
|
| Cash Flow From Continuing Financing Activities |
|
-6.49
-241.85%
|
4.57
-74.97%
|
18.27
+95.54%
|
9.34
|
| Net Issuance Payments Of Debt |
|
-0.53
+40.63%
|
-0.89
-31.26%
|
-0.68
+15.94%
|
-0.80
|
| Issuance Of Debt |
|
—
|
—
|
0.00
-100.00%
|
10.00
|
| Repayment Of Debt |
|
-0.53
+40.63%
|
-0.89
-31.26%
|
-0.68
+15.94%
|
-0.80
|
| Long Term Debt Issuance |
|
—
|
—
|
0.00
-100.00%
|
10.00
|
| Long Term Debt Payments |
|
-0.53
+40.63%
|
-0.89
-31.26%
|
-0.68
+15.94%
|
-0.80
|
| Net Long Term Debt Issuance |
|
-0.53
+40.63%
|
-0.89
-31.26%
|
-0.68
+15.94%
|
-0.80
|
| Net Common Stock Issuance |
|
4.28
-23.83%
|
5.62
-33.45%
|
8.45
+40133.33%
|
0.02
|
| Proceeds From Stock Option Exercised |
|
—
|
5.50
|
0.00
-100.00%
|
0.01
|
| Net Other Financing Charges |
|
-10.24
-6146.34%
|
-0.16
-101.56%
|
10.49
+3.73%
|
10.12
|
| Changes In Cash |
|
-2.37
+56.36%
|
-5.42
+31.91%
|
-7.96
-650.52%
|
-1.06
|
| Effect Of Exchange Rate Changes |
|
0.02
+142.86%
|
-0.05
+80.00%
|
-0.24
+89.27%
|
-2.28
|
| Beginning Cash Position |
|
15.30
-26.34%
|
20.77
-28.32%
|
28.98
-10.35%
|
32.33
|
| End Cash Position |
|
12.96
-15.33%
|
15.30
-26.34%
|
20.77
-28.32%
|
28.98
|
| Free Cash Flow |
|
-13.64
+32.91%
|
-20.33
+8.25%
|
-22.15
+10.85%
|
-24.85
|
| Common Stock Issuance |
|
4.28
-23.83%
|
5.62
-33.45%
|
8.45
+40133.33%
|
0.02
|
| Earnings Losses From Equity Investments |
|
0.04
+0.00%
|
0.04
|
0.00
|
0.00
|
| Interest Paid CFO |
|
-0.19
-188.06%
|
-0.07
+44.63%
|
-0.12
+26.67%
|
-0.17
|
| Interest Received CFO |
|
0.34
-63.81%
|
0.93
+3.20%
|
0.91
+386.56%
|
0.19
|
| Issuance Of Capital Stock |
|
4.28
-23.83%
|
5.62
-33.45%
|
8.45
+40133.33%
|
0.02
|
| Taxes Refund Paid |
|
-0.01
+0.00%
|
-0.01
+64.52%
|
-0.03
+22.50%
|
-0.04
|
| Cash From Discontinued Financing Activities |
|
-0.12
-238.55%
|
0.08
+170.94%
|
-0.12
|
—
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|